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Abstract 
Background: Despite its impact on female health worldwide, no efforts have been made to depict the global archi-
tecture of ovarian cancer research and to understand the trends in the related literature. Hence, it was the objective 
of this study to assess the global scientific performance chronologically, geographically and in regards to economic 
benchmarks using bibliometric tools and density equalizing map projections.
Methods: The NewQIS platform was employed to identify all ovarian cancer related articles published in the Web of 
Science since 1900. The items were analyzed regarding quantitative aspects (e.g. publication date, country of origin) 
and parameters describing the recognition of the work by the scientific community (e.g. citation rates).
Results: 23,378 articles on ovarian cancer were analyzed. The USA had the highest activity of ovarian cancer research 
with a total of n = 9312 ovarian cancer-specific publications, followed by the UK (n = 1900), China (n = 1813), 
Germany (n = 1717) and Japan (n = 1673). Ovarian cancer-specific country h-index also showed a leading position 
of the USA with an h-index (HI) of 207, followed by the UK (HI = 122), Canada (HI = 99), Italy (HI = 97), Germany 
(HI = 84), and Japan (HI = 81). In the socio-economic analysis, the USA were ranked first with an average of 175.6 
ovarian cancer-related publications per GDP per capita in 1000 US-$, followed by Italy with an index level of 46.85, the 
UK with 45.48, and Japan with 43.3. Overall, the USA and Western European nations, China and Japan constituted the 
scientific power players publishing the majority of highly cited ovarian cancer-related articles and dominated interna-
tional collaborative efforts. African, Asian and South American countries played almost no visible role in the scientific 
community.
Conclusions: The quantity and scientific recognition of publications related to ovarian cancer are continuously 
increasing. The research endeavors in the field are concentrated in high-income countries with no involvement 
of lower-resource nations. Hence, worldwide collaborative efforts with the aim to exchange epidemiologic data, 
resources and knowledge have to be strengthened in the future to successfully alleviate the global burden related to 
ovarian cancer.
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Background
Ovarian cancer is the most lethal gynecological tumor in 
high income-countries; it represents the seventh-most 
common female cancer worldwide [1, 2]. In the United 
States, approximately 22,000 new ovarian cancer cases 
are diagnosed annually, 14,200 related deaths occur each 
year [3]. The majority of invasive ovarian malignancies 
originate from epithelial cells. Each histotype—high-
grade serous, low-grade serous, mucinous, clear cell and 
endometrioid—exhibits distinct clinical and pathological 
characteristics [4].
During the last three decades, multiple breakthrough 
discoveries have been reported in the field: for the last 
10 years it has been accepted that two types of epithelial 
ovarian cancers exist [1, 5]. Type I tumors include low-
grade serous, endometrioid and clear cell histologies [6, 
7]. The association of Type I cancers with endometriosis 
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was found in 2012. This benign condition increases the 
risk of low-grade serous and endometrioid cancers by 
approximately twofold, for clear cell subtypes by three-
fold [1, 8]. Also, ARID1A gene mutations were described 
for endometriosis-associated endometrioid and clear cell 
cancers [9]. Type II high-grade serous carcinomas are the 
most common ovarian malignancies. In 2006, Medeiros 
et al. presumed their origin from the fimbriae of the fal-
lopian tube [10]. In the last years, the identification of rel-
evant somatic and germline mutations gained relevance 
as a first step towards screening strategies and novel tar-
geted therapies: KRAS, BRAF, ERBB2, CTNNB1, PTEN, 
PIK3CA, ARID1A, PPP2R1A, and BCL2 mutations were 
found in Type I carcinomas. 96% of high-grade serous 
Type II tumors had TP53 mutations [1, 5, 11]. In 1994 
and 1995, BRCA 1/2 mutations were described in heredi-
tary Type II cancers; since then they have gained impor-
tance for clinical risk prediction and patient counseling 
[12, 13].
The volume of scientific literature in oncology 
increased rapidly during the last 50  years [14]. System-
atic evaluation of research output is necessary to guide 
individual reading, to plan research activities accord-
ing to shortcomings and to quantify individual and col-
laborative productivity on national and international 
level. These assessments play an integral role in career 
decisions, allocation of grant funding and prioritizing 
research resources [14]. Scientometric methods provide 
the standardized analysis of journal articles in reference 
to their content and citations describing developments 
in origin and dissemination of published data. Specific 
to ovarian cancer, no systematic evaluation of the global 
scientific output is available to date, and no efforts have 
been made to understand trends in the related literature. 
Therefore, the topic of ovarian cancer was elected by 
the New Quality and Quantity Indices in Science (New-
QIS) project [15] for a scientometric in-depth analysis. 
The study objectives included (1) the assessment of the 
worldwide publication output regarding quantitative 
aspects, parameters describing the recognition within 
the scientific community (e.g. citation rates) and research 
networks as well as (2) the evaluation of the country-
specific productivity related to socio-economic variables. 
Also, we identified the leading journals publishing in the 
field and the most recognized articles since 1900.
Methods
NewQIS study
We employed the established NewQIS platform [15, 16] 
to conduct this study. The NewQIS platform was devel-
oped in 2009 as a multidisciplinary project involving sci-
entists from different backgrounds such as engineering, 
computer sciences and medicine and numerous studies 
were published so far using the platform [17–32]. It con-
stitutes a novel tool that was designed for the objective, 
precise and reliable scientometric analyses of research 
productivity based on validated protocols. Benefits of 
the platform include the efficient and standardized inves-
tigation of the scientific progress chronologically and 
geographically, the visualization of the results in expres-
sive global maps via density equalizing map projections 
(DEMP), as well as unique evaluation tools deciphering 
national and international scientific relations and gender 
distribution among authors.
Data source
We used an index database of the Web of Science (WoS 
core collection, Thomson Scientific) and analyzed the 
total research productivity by quantification of ovarian 
cancer-specific publications. Parameters describing the 
articles’ recognition by the scientific community were 
assessed based on the number of related citations, i.e. 
h-indices and citation rates.
The WoS was selected as data source because of its 
unique Citation Report function allowing the extraction 
of citation performance parameters [33]. We refrained 
from extracting data from other platforms such as 
Google Scholar or Scopus due to the lack of data congru-
ence in these three databases hampering triangulating, 
comparing and integrating data related to ovarian cancer 
research since 1900 [34].
Search strategy
We conducted a “title” search for the time period of 1900 
(01-01) to 2014 (31-12). The search term [“(ovarian OR 
ovary) AND (cancer OR neoplasm OR carcinoma)”] was 
used. The year 2015 was excluded to avoid incomplete 
data acquisition at the time the study was performed. 
We used the filter option “document type” to restrict our 
search to “original articles” as described previously [15].
Data analysis and categorization
Articles were saved in a plain text format using the down-
load application provided by the WoS. All related meta-
data were collected in an interim database and, analyzed 
according to the following criteria: originating country, 
language, citations, cited references, authors, journal, 
year published and subject categories. The subject cat-
egories represent standard categories assigned to every 
publication by the Journal Citation Reports (provided by 
the Thompson Reuters/Institute of Scientific Informa-
tion) during the publication process. We computed the 
country-specific modified h-index (HI) and the citation 
rate (CR, number of all citations per total ovarian can-
cer publication volume). In 2005, the HI was developed 
by Jorge Hirsch to assess the recognition of an author’s 
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research performance in the scientific community [35]. 
In our study, this proxy measure was adapted to evalu-
ate the productivity of single countries in ovarian can-
cer research and therefore termed “modified HI”. Also, 
a glossary was added in the Additional file  1 describing 
important terms used in this manuscript.
Density equalizing map projections (DEMP)
DEMP visualize benchmarking processes by the crea-
tion of anamorphic world maps. After the transfer of the 
metadata to excel charts and parameter analysis, DEMP 
were calculated based on the algorithms of Gastner and 
Newman. Therefor, the territories of countries publishing 
ovarian cancer research were resized in proportion to the 
selected criteria (i.e. the total number country-specific 
articles) [36].
Socio‑economic analysis
In order to quantify country-specific contributions to 
ovarian cancer research in regards to their economic 
resources and manpower, we evaluated research pro-
ductivity in relation (1) to the gross domestic product 
(GDP) per capita, (2) to the total economic power index 
GDP per 1000 billion US-$ and (3) to the population size. 
Economic facts were obtained from the World Economic 
Outlook Database of the International Monetary Fund of 
2014 [37]. Only countries with a minimum of 50 ovarian 
cancer publications were included. We also collected the 
absolute numbers of ovarian cancer incidence and the 
crude rate (defined as the new cancer cases diagnosed 
in a specific year per 100,000 persons at risk) of the 25 
countries that have published more than 100 ovarian 
cancer items during the investigated time span. The data 
reflect the incidence of ovarian cancer in 2012 and were 
obtained from http://globocan.iarc.fr/Pages/summary_
table_pop_sel.aspx. Based on these numbers we calcu-
lated the ratio of country-specific articles per each new 
ovarian cancer case.
Analysis of ovarian cancer research collaborations
To determine research collaborations from a global view-
point, affiliations of authors were analyzed and chart dia-
grams were computed as previously described [38]. We 
defined an article as “collaborative” if at least two authors, 
who work in different countries as stated in the affilia-
tions, contributed to the work. Publications with shared 
authorship were counted one time only (independent of 
the number of authors from the same country defined in 
the affiliations) towards the complete count of joint pub-
lications this specific country is involved in. For exam-
ple, when 10 publications were analysed of which eight 
were affiliated with the USA, five with the UK and three 
items were joint publications, these were counted as 3 
out of 8 for the USA and 3 out of 5 for the UK. Also, we 
related the total count of collaborative items to the over-
all number of publications for each investigated country. 
For example, 2240 items were published by US-Ameri-
can authors in a joint effort with other countries. These 
were related to the overall scientific productivity of the 
USA represented by 9312 items (24%). 747 collaborative 
publications were identified for the UK; these accounted 
for 39% out of 1900 items. In Fig. 3, vectors represent the 
productivity of collaborations for each pair of countries. 
These are proportional in line width and shade of grey to 
the number of collaborations.
Results
General parameters
In 115 years, a total of 23,378 original articles were pub-
lished in the WoS. The publication activities increased 
continuously throughout the decades: Until the 1950s 
we identified up to 10 articles each year; this number 
increased to more than 100 publications/year from 1979 
onwards and doubled after 1984. In the next decade, the 
productivity increased to more than 500 annual items 
and doubled again after 2008. In 2014, 1540 articles were 
published (Fig. 1a). The number of participating authors 
per publication increased from 2.5 authors in 1972 to 
8.18 authors per ovarian cancer-related article in 2014.
Country‑specific analysis
A total of 99 countries participated in the publication of 
all articles. The majority of publication volume originated 
from a small number of countries: The United States of 
America (USA) was the most productive with 9312 ovar-
ian cancer-specific articles. It was followed by the United 
Kingdom (UK, 1900 articles), China (1813 articles), Ger-
many (1717 articles), Japan (1673 articles) and Italy (1672 
articles). Hence, DEMP analysis demonstrated a dis-
torted world map with the main focus on North America 
and Western Europe and a prominent China and Japan 
(Fig.  1b). Asian, South American and African countries 
occupied only minimal areas on the cartogram.
Citation analysis
The citation count of yearly published articles showed a 
course similar to the annual publication activity: After a 
very modest increase until 1974 the citations increased 
steadily with peaks in 1979, 1989, 1994, 1996, 2004. After 
2005, we documented a steep decline in citation numbers 
until 2014 with the exception of a small plateau in 2008 
(Fig. 2a).
Country-specific citation analysis indicated a lead-
ing position of the USA with 354,891 citations (41.2% 
of all citations). It was followed by the UK (71,562 cita-
tions), Canada (55,964 citations), Italy (49,422 citations), 
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Japan (35,995 citations), and Germany (34,278 citations) 
(Fig.  2b). In contrast to publication activities, China 
dropped from third to position 10 when citations were 
quantified.
The USA dominated the country-specific HI analysis 
(HI of 207), and was followed by the UK (HI  =  122), 
Canada (HI = 99), Italy (HI = 97), Germany (HI = 84), 
and Japan (HI  =  81) (Table  1). Regarding the cita-
tion rate (CR) of countries with a minimum of 30 
articles published on ovarian cancer, we identified 
Canada (CR  =  43.52) in the leading position. Then 
Finland (CR  =  39.17), Hungary (CR  =  38.81), the 
USA (CR = 38.11) and the UK (CR = 37.66) were fol-
lowed by the Western European countries Belgium 
(CR  =  36.92), Sweden (CR  =  36.61), the Netherlands 
(CR = 34.03), Norway (CR = 31.8), Italy (CR = 29.56) 
and France (CR  =  23.79). China dropped to a CR of 
11.05 (Table 2).
Fig. 1 Publication output. a Number of published items per year. b Density equalizing map of the global ovarian cancer research activity between 
1900 and 2014. Colors and territorial sizes indicate numbers of ovarian cancer publications per country
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Socio‑economic analysis of ovarian cancer research
When the country-specific publications were related to 
the gross domestic product (GDP) per capita, the USA 
was ranked first with an average of 169.9 ovarian cancer-
related publications per GDP per capita in 1000 US-$ 
(Q1). The USA was followed by China as the first middle-
income country in the ranking (Q1: 140.5), the UK (Q1: 
50.4), Italy (Q1: 48.5) and Japan (Q1: 44.3) (Table 3). 
For the total economic power index GDP, Denmark was 
positioned at the first place with a total of 1293.2 ovarian 
cancer-specific articles per 1000 billion US-$ GDP (Bio 
US-$ GDP, Q2), followed by Israel (Q2: 1272). Amongst 
the high-income countries, the UK ranked at position 12 
(Q2: 667.1), followed by Belgium (Q2: 629) and the USA 
(Q2: 534.6). China (Q2: 157) occupied the 4th rank of the 
middle-income countries and the 32nd position of all 
Fig. 2 Citation analysis. a Number of citations between 1950 and 2014. b Density equalizing map of the number of citations. Colors and territorial 
sizes indicate numbers of citations per country
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countries with more than 50 ovarian cancer-specific arti-
cles (Table 3).
Denmark was positioned first when the ovarian cancer 
research output was related to population size. Here, 80.3 
ovarian cancer-specific publications were authored per 1 
million citizens. It was followed by Norway (77.9 publi-
cations/1 million citizens), Iceland (65.5 publications/1 
million citizens), Finland (62.2 publications/1 million cit-
izens) and Sweden at position 5 (54.8 publications/1 mil-
lion citizens). Other productive countries were the USA 
(29.7 publications/1 million citizens), UK (29.8 publica-
tions/1 million citizens) and China (13.4 publications/1 
million citizens).
Furthermore, Israel took the lead having published one 
article per newly diagnosed ovarian cancer case based 
on the incidence data of 2012. It was followed by Nor-
way (0.94 articles per new ovarian cancer case), Denmark 
(0.83 articles per new ovarian cancer case), Sweden (0.79 
articles per new ovarian cancer case), the Netherlands 
(0.74 articles per new ovarian cancer case) and Finland 
(0.74 articles per new ovarian cancer case). The USA was 
ranked 11th; countries such as China, Russia and India 
were ranked last amongst the 25 investigated nations 
(Table  4). A DEMP shows the absolute ovarian cancer 
incidence numbers of the 25 counties that have published 
more than 100 articles during the investigated time span 
(Additional file 2: Figure S1).
Publishing journals and landmark articles
1685 journals published ovarian cancer-related arti-
cles since 1900. The most prolific journal was “Gyneco-
logic Oncology” with 2710 articles and a related citation 
rate (CR) of 23.91 followed by “International Journal of 
Gynecological Cancer” (968 articles/CR  =  11.06) and 
“Cancer Research” (637 articles/CR  =  80.81). We dis-
played the top 15 journals including number of articles, 
citations and CR (Additional file 3: Table S1, Additional 
file 4: Figure S2) and identified the ten most cited articles 
in the area of ovarian cancer research (Additional file 5: 
Table S2).
Table 1 Modified h-indices
Rank Country h‑index
1 United States 207
2 United Kingdom 122
3 Canada 99
4 Italy 97
5 Germany 84
6 Japan 81
7 Netherlands 78
8 Australia 74
9 France 70
10 Sweden 68
11 Belgium 58
12 China 57
13 Finland 55
14 Denmark 54
15 Norway 54
16 Israel 52
17 Austria 51
18 Spain 49
19 Switzerland 48
20 South Korea 45
21 Greece 42
22 Poland 40
23 Taiwan 37
24 Turkey 23
25 India 22
26 Ireland 22
27 South Africa 20
28 Hungary 20
29 Portugal 20
30 Czech Republic 19
31 Russia 18
32 Thailand 18
33 Singapore 18
34 Iceland 18
35 Brazil 16
36 New Zealand 15
37 Mexico 14
38 Slovakia 14
39 Slovenia 13
40 Chile 13
41 Croatia 12
42 Egypt 12
43 Malaysia 12
44 Iran 10
45 Saudi Arabia 10
46 Argentina 10
47 Belarus 10
48 Serbia 9
49 Romania 8
The table summarizes the h-indices related to research on ovarian cancer and 
published by the countries investigated
Table 1 continued
Rank Country h‑index
50 Pakistan 8
51 Lithuania 8
52 Bulgaria 7
53 Latvia 6
54 Ukraine 4
55 Tunisia 3
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Ovarian cancer subject area analysis
The leading subject categories of ovarian cancer research 
were “Oncology” with 13,649 publications cited 363,896 
times, “Obstetrics & Gynecology” (6878 publications, 
128,161 citations), and—following with a considerable 
gap—“Pathology” (1238 publications and 31,921 cita-
tions) (Additional file 6: Figure S3A). The areas “General 
& Internal Medicine” (35,221 citations) and “Genetics 
& Hereditary” (33,842 citations) showed a high CR rela-
tive to the total number of publications indicating a high 
impact of published work in the field.
We performed a subject area analysis for the ten most 
active countries in ovarian cancer research to identify their 
particular scientific focus: Up to 80% of all publications 
in nine of the ten countries were attributed to “Oncol-
ogy” and “Obstetrics & Gynecology”. China published a 
high percentage of articles in “Research and Experimen-
tal Medicine”, “Biochemistry and Molecular Biology” as 
well as “Cell Biology”. Researchers from the UK, Australia, 
France and Canada focused on the area of “Genetics”. Japa-
nese scientists dedicated a high percentage of their work to 
the subject category of “Pathology”. “General and Internal 
Medicine” was popular among researchers from France 
and the UK (Additional file 6: Figure S3B).
International ovarian cancer collaborations
We identified 3697 international collaborations pub-
lishing on ovarian cancer, 74% were bilateral (2733 
items) and 15.4% trilateral co-operations (568 items). 
Joint research efforts were clearly dominated by scien-
tists and institutions situated in the USA. US-American 
authors published 24% of all publications in co-operation 
with other countries, and collaborated with 13 different 
countries in total. The most active collaborations were 
established between the USA and Canada (433 collabo-
rative papers), followed by US-American co-operations 
with the UK (385 papers), China (300 papers), Italy (291 
papers) and Germany (284 papers) (Fig. 3).
Discussion
During 115 years, a total of 23,378 original research arti-
cles were published in the WoS. The number of publica-
tions rose slowly until the seventies, when a steep and 
steady increase of research productivity started. This 
pattern is detected for most biomedical research as 
exemplified by studies on medical curare use or bacterial 
meningitis [39, 40]. From 1900 to 1950, only 139 articles 
related to ovarian cancer were part of the WoS data-
base. This is attributed to the following: Overall research 
activities were lower since the recognition and funding 
Table 2 Ovarian cancer-specific citation rates
The table summarizes the citation rates related to ovarian cancer research and 
published by investigated countries with a minimum of 30 publications
Rank Country Citation rate
1 Canada 43.52
2 Finland 39.17
3 Hungary 38.81
4 United States 38.11
5 United Kingdom 37.66
6 Belgium 36.92
7 Sweden 36.61
8 Netherlands 34.03
9 Norway 31.80
10 Australia 30.55
11 Italy 29.56
12 Portugal 29.44
13 Switzerland 29.43
14 Spain 28.76
15 Denmark 28.53
16 Ireland 28.51
17 Mexico 27.16
18 Israel 25.96
19 Greece 24.91
20 France 23.79
21 Austria 22.58
22 Slovenia 22.47
23 South Africa 22.35
24 Japan 21.52
25 New Zealand 20.66
26 Germany 19.96
27 Poland 19.33
28 Taiwan 18.17
29 Thailand 17.85
30 Czech Republic 17.16
31 Slovakia 16.69
32 South Korea 15.30
33 Egypt 13.81
34 Singapore 13.03
35 India 12.65
36 Malaysia 12.31
37 Brazil 11.90
38 China 11.05
39 Romania 10.50
40 Saudi Arabia 9.30
41 Croatia 8.82
42 Turkey 8.59
43 Russia 7.55
44 Iran 4.34
45 Serbia 4.14
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of scientists were not predominantly determined by their 
productivity. In 1915, Japanese researchers could provoke 
cancer in an animal model for the first time. Since then 
pathogenetic mechanisms of cancer shifted into the sci-
entific focus paving the way to today’s understanding of 
the disease [41]. English was not the common scientific 
language at this time. Hence, a considerable amount of 
non-English publications issued before 1950 is not repre-
sented in our analysis.
The late 1970s was an era when ovarian cancer-associ-
ated research gained increasing popularity (Fig. 1). Then, 
major scientific progress happened in the field as indi-
cated by the first highly cited publication linking ovarian 
cancer and incessant ovulation [42–46]. The output grew 
Table 3 Socio-economic analysis of  ovarian cancer research of  the most active countries in  ovarian cancer research. 
Source for GDP (Currency in 1000 Billion US Dollars) and GDP per capita (Currency in 1000 US Dollars) in 2014 was the 
World Economic Outlook Database of the International Monetary Fund of 2014. (Threshold: 50 ovarian cancer-specific 
publications)
Country Rank Number 
of articles
GDP (in 1000 
Bill. US$)
Articles/GDP 
(1000 Bill. US$)
Rank ratio 
(Articles/GDP 
in economic 
group)
GDP per capita 
(in US$)
Articles/GDP 
per capita (in 
1000 US$)
Rank ratio 
(Articles/GDP 
per capita 
in economic 
group)
USA 1. 9312 17.420 534.6 HIG 14 54,800 169.9 HIG 1
China 2. 1813 10.360 175.0 MIG 4 12,900 140.5 MIG 1
UK 3. 1900 2.848 667.1 HIG 12 37,700 50.4 HIG 2
Italy 4. 1672 2.129 785.3 HIG 9 34,500 48.5 HIG 3
Japan 5. 1673 4.770 350.7 HIG 22 37,800 44.3 HIG 4
Germany 6. 1717 3.820 449.5 HIG 18 44,700 38.4 HIG 5
Canada 7. 1286 1.794 716.8 HIG 11 44,500 28.9 HIG 6
India 8. 150 2.048 73.2 MIG 6 5800 25.9 MIG 2
France 9. 878 2.902 302.5 HIG 24 40,400 21.7 HIG 7
Poland 10. 458 0.552 829.4 HIG 8 24,400 18.8 HIG 8
Australia 11. 742 1.483 500.3 HIG 16 46,000 16.1 HIG 9
Netherlands 12. 762 0.880 865.5 HIG 7 47,400 16.1 HIG 10
South Korea 13. 561 1.410 397.9 HIG 20 35,400 15.8 HIG 11
Turkey 14. 290 0.813 356.6 MIG 1 19,600 14.8 MIG 3
Sweden 15. 522 0.559 933.6 HIG 6 44,700 11.7 HIG 12
Israel 16. 388 0.305 1272.1 HIG 2 33,400 11.6 HIG 13
Greece 17. 295 0.246 1197.2 HIG 4 25,800 11.4 HIG 14
Spain 18. 370 1.400 264.3 HIG 25 33,000 11.2 HIG 15
Denmark 19. 449 0.347 1293.2 HIG 1 44,300 10.1 HIG 16
Austria 20. 450 0.436 1031.9 HIG 5 45,400 9.9 HIG 17
Finland 21. 337 0.276 1219.7 HIG 3 40,500 8.3 HIG 18
Belgium 22. 332 0.528 629.0 HIG 13 41,700 8.0 HIG 19
Russia 23. 166 2.057 80.7 HIG 28 24,800 6.7 HIG 20
Taiwan 24. 265 0.530 500.5 HIG 15 43,600 6.1 HIG 21
Norway 25. 391 0.512 764.3 HIG 10 65,900 5.9 HIG 22
South Africa 26. 71 0.341 208.1 MIG 2 12,700 5.6 MIG 4
Switzerland 27. 306 0.679 450.7 HIG 17 55,200 5.5 HIG 23
Thailand 28. 74 0.374 198.0 MIG 3 14,400 5.1 MIG 5
Brazil 29. 70 2.244 31.2 MIG 7 15,200 4.6 MIG 6
Iran 30. 62 0.403 154.0 MIG 5 16,500 3.8 MIG 7
Czech Republic 31. 74 0.206 359.9 HIG 21 28,400 2.6 HIG 24
Hungary 32. 57 0.130 439.5 HIG 19 24,300 2.3 HIG 25
Portugal 33. 54 0.228 236.6 HIG 26 26,300 2.1 HIG 26
Ireland 34. 75 0.246 305.1 HIG 23 46,800 1.6 HIG 27
Singapore 35. 70 0.308 227.3 HIG 27 81,300 0.9 HIG 28
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dramatically in the nineties, which coincided with more 
landmark findings such as the discovery of the BRCA 
genes [47]. After 2008, annual research productivity 
increased to more than 1000 papers when new hypoth-
eses regarding the origin of high-grade serous subtypes 
[10] and the association of ovarian cancers with ARID1A 
mutations and endometriosis were proposed [8, 9]. Also, 
publications assessing novel treatment strategies such 
as pathway inhibitor (e.g. PARP inhibitors) or antibody-
based therapies were mainly released in the last 7 years.
Resembling the growing volume of published papers, 
the absolute citation count of ovarian cancer-related pub-
lications showed a steady increase until 2005 (Fig.  2a). 
Landmark papers (included in Additional file 5: Table S2) 
contributed to peaks in the graph: In 1979, Casagrande 
et al. [42] proposed the link between ovarian cancer and 
incessant ovulation. In 1989, two highly cited papers were 
published, which explored the pathogenetic relevance of 
HER2neu receptors and the efficacy of taxol as ovarian 
cancer treatment [48, 49]. In 1994 and 1995, the ovarian 
cancer susceptibility genes—BRCA 1 and 2—were iden-
tified. Related articles lead to citation peaks in 1994 and 
1996 [12, 13]. A meta-analysis investigating the ovarian 
cancer risk of 8139 patients with BRCA1 and BRCA2 
mutations was published in 2003 and associated with the 
citation peak in 2004 [50]. The decrease in citations after 
2005 is linked to a delay of up to 8 years between publi-
cation and appropriate scientific recognition of an article 
represented by a maximum number of citations [51].
When country-specific ovarian cancer research pro-
ductivity was analyzed, the leading position of the USA 
became evident. This finding aligns with a benchmarking 
study assessing the scientific output from 1961 to 2007 
related to 22 organ systems. With 1,893,800 of 5,527,558 
publications, the USA identified as the most productive 
nation [52]. The success of the USA points to its com-
mitment to allocate major resources towards biomedical 
research, e.g. the NCI awarded $100.6 million ovarian 
cancer funding in 2003 (http://www.cancer.gov/research/
progress/snapshots/ovarian). In our study, the USA was 
Table 4 The table depicts the absolute incidence numbers and the crude rate (defined as the new cancer cases diagnosed 
in  a specific year per  100,000 persons at  risk) of  ovarian cancer of  the 25 countries having published more than  100 
related items and the ratio of country-specific articles per each new ovarian cancer case
The data reflect the incidence of ovarian cancer in 2012
Rank Country Article count Incidence in 2012 Crude rate in 2012 Article/new case in 2012
1 Israel 388 380 9.8 1.02
2 Norway 391 418 16.9 0.94
3 Denmark 449 544 19.3 0.83
4 Sweden 522 659 13.8 0.79
5 Netherlands 762 1025 12.2 0.74
6 Finland 337 457 16.6 0.74
7 Austria 450 636 14.8 0.71
8 Australia 742 1424 12.4 0.52
9 Switzerland 306 621 15.8 0.49
10 Canada 1286 2648 15.2 0.49
11 United States 9312 20,874 13.1 0.45
12 Belgium 332 840 15.3 0.40
13 Greece 295 915 15.9 0.32
14 United Kingdom 1900 6692 21 0.28
15 Italy 1672 5911 19 0.28
16 Germany 1717 6673 16.1 0.26
17 South Korea 561 2349 9.8 0.24
18 France 878 4592 14.1 0.19
19 Japan 1673 8921 13.7 0.19
20 Turkey 290 2400 6.4 0.12
21 Spain 370 3236 13.7 0.11
22 Poland 458 4456 22.5 0.10
23 China 1813 34,575 5.3 0.05
24 Russia 166 13,373 17.4 0.01
25 India 150 26,834 4.4 0.01
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followed by the UK, China, Germany and Japan regard-
ing research productivity. Glynn et  al. [14] described a 
similar pattern for breast cancer, where the USA, the UK, 
Germany and Japan were also among the top five coun-
tries. China constitutes an exception: It ranked second 
for ovarian cancer research productivity but dropped to 
position 12 for breast cancer.
Citations indicate the relevance of a published item 
[14]. In our study, the USA, the UK and Canada domi-
nated the ranking in term of citation counts, HI and CR. 
These results correspond to other studies in obstetrics 
and gynecology, e.g. on smoking and pregnancy. Here, 
the USA, the UK and Canada also achieved the highest 
modified HI of 128, 79 and 62 and the highest citation 
rates of 41.4, 8.6 and 5.3%, respectively [38]. In order to 
define the commitment of single countries in ovarian 
cancer research, we investigated scientific productivity 
in terms of socio-economic abilities and demonstrated 
two important features: First, the USA lost its leading 
position and other—mostly European—nations gained 
importance. Denmark, Norway, Iceland, Finland and 
Sweden ranked in the top five when article count was 
analyzed in relation to number of citizens. When the 
total number of articles was related to the total economic 
power, Israel, Iceland, Denmark and Finland were lead-
ing the field. Second, when we focused on countries with 
a large population and high total GDPs such as China, 
their relative contribution to the global research output 
remained small compared to the USA and Europe.
Taken together, the worldwide research architecture on 
ovarian cancer revealed that the USA and Western Euro-
pean nations, China and Japan constitute the scientific 
power players. They publish the majority of highly cited 
ovarian cancer-related articles and dominate interna-
tional collaborative efforts. A strong dedication of single 
countries to ovarian cancer research is also indicated by 
the prominent position of European nations—e.g. the 
Scandinavian countries in particular—when research 
productivity was related to socio-economic benchmarks. 
These findings coincide with other benchmarking studies 
[52] and with the fact that the highest incidence rates of 
ovarian cancer (e.g. Northern and Western Europe with 
incidences of 13.3 and 11.3 per 100,000 person-years as 
well as Northern America with an incidence of 10.7 per 
100,000 person-years) are found in areas with the great-
est research productivity. This association underlines 
Fig. 3 International ovarian cancer research collaborations. Greyscale and bar thickness indicate intensity of collaborations. First ciphers in brackets 
indicate total publication numbers. Second ciphers indicate number of collaborative publications. Threshold: 5 collaborations
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that the nations, which should prioritize ovarian cancer 
research to alleviate the burden among its female inhabit-
ants, actually do so. Taking the ratio of articles per every 
new ovarian cancer case (based on the absolute incidence 
data of 2012) into account, we can demonstrate a similar 
picture. The Scandinavian countries and the Netherlands 
were among the leading nations. By contrast, Canada and 
the USA were ranked only in the middle field with a pub-
lication output of around one article per two new ovarian 
cancer cases. Although China had a low incidence rate 
of 3.2 per 100,000 person-years reported for 2002, secu-
lar epidemiological trends project increasing numbers 
for the future [53]. This might explain why China sup-
ports ovarian cancer research as indicated by the strong 
research productivity [54].
The public health burden of ovarian cancer is signifi-
cant. No considerable improvements of survival rates 
or decrease in morbidity and mortality have been seen 
over the past decades. Hence, research activity needs to 
be fostered, and collaborative research efforts are crucial 
to tackle the challenges in the field. National and inter-
national networks are equipped to do this by sharing 
resources, facilities and ideas leading to landmark pub-
lications [55]. In our study, the USA was the most pre-
ferred nation for collaborations based on its outstanding 
financial support and scientific infrastructure. We iden-
tified the most productive co-operations between the 
USA, Canada as well as the UK. This finding is linked to 
the areal proximity and cultural/language similarities, 
which contribute to the high productivity and quality of 
research produced by each of these countries. Addition-
ally, our observation of increasing author numbers per 
ovarian cancer publication reflects the development of 
strong research networks around the globe. The Ovar-
ian Cancer Association Consortium (OCAC) serves as 
an example for highly prolific global networks. Founded 
in 2005, this multidisciplinary, international group pub-
lished more than 60 high impact papers in the areas of 
genetics and epidemiology.
According to the International Agency for Research on 
Cancer in 2012, 58% of ovarian cancer cases occurred in 
less developed nations [56]. Countries with the highest 
incidence rates of ovarian cancer were Fiji (age-stand-
ardized rate per 100,000: 14.9), Latvia (age-standardized 
rate per 100,000: 14.2) and Bulgaria (age-standardized 
rate per 100,000: 14.0) [56]. Although these countries 
experience a significant burden due to the disease, they 
were underrepresented on our map of ovarian cancer 
research. We did not identify one article published by 
Fiji. Latvia published 10 articles cited 112 times and Bul-
garia issued 10 articles cited 90 times. Fiji was not part 
of any collaborative network. Latvia participated in only 
five multinational collaborations and Bulgaria in eight 
bilateral collaborations. We want to point out the neces-
sity—and almost the ethical responsibility—to include 
lower-resource countries with high incidence rates in sci-
entific collaborations. Here epidemiological data, ideas 
and gained knowledge can be exchanged and benefit all 
participants.
To date, most ovarian cancer related articles were pub-
lished in the subject categories of Oncology, Obstetrics/
Gynecology as well as Pathology. This is not surpris-
ing. However, we found a shift in publication activity 
to areas such as Genetics and Internal Medicine. This 
development is linked to highly cited articles published 
by recently founded genetic-epidemiological consortia, 
i.e. OCAC or Ovarian Tumor Tissue Array Consortium. 
The increase in the subject category of Internal Medi-
cine is explained by the growing number of high quality 
publications in leading journals such as the “New Eng-
land Journal of Medicine”, “Nature” or “Lancet”, which 
are attributed to this category. Also, it reflects the grow-
ing interest of internal medicine physicians in the care of 
ovarian cancer patients.
In this study, we analyzed ovarian cancer research by 
assessing the country-specific publication output associ-
ated with this topic. DEMP analysis provided the visu-
alization of computed geospatial information regarding 
our findings, which is a unique strength of this study. 
Researchers from different countries and continents 
can benefit from our data since they provide objec-
tive insights about the status of ovarian cancer research 
in their homeland or a specific country of interest. In 
particular, they are able to plan future research initia-
tives and collaborations tailored to meet the identified 
needs. Further, representatives of funding institution can 
use the presented results for the strategic allocation of 
resources according to obvious shortcomings. A limita-
tion of this study is linked to the preference of the WoS to 
index mostly English publications. This translates into an 
underrepresentation of non-English items and an under-
estimation of the total article number, which seems to 
skew our findings. Since high quality research is mostly 
published in English journals and the WoS catalogs 90% 
of cited and 80% of published items related to a specific 
topic [57], our search identified the majority of relevant 
published items linked to ovarian cancer. Hence, the bias 
can be considered as limited. Overall, we assessed three 
types of bibliometric indicators gauging the publication 
activity on ovarian cancer: Quantitative aspects to meas-
ure the productivity of the research community, perfor-
mance indicators to reflect the quality of scientific output 
and structural indicators to visualize the interconnected-
ness of research [58]. Limitations are linked to the evalu-
ation of “qualitative” citation parameters. It is generally 
accepted that high citation numbers reflect outstanding 
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scientific recognition. This relationship might be skewed 
due to the Matthew effect: Scientists of acknowledged 
standing will be cited more than little-known authors, 
and the citation count of their papers will increase dis-
proportionally after their publications gained some initial 
popularity [59]. Also, the use of performance indicators 
(e.g. the citation rate) only helps gauge the quality of pub-
lished research. Because citation habits and dynamics 
are highly variable in the investigated fields of research, 
all variables based on citation frequency are problem-
atic and rather mirror the recognition of fellow scientists 
than truly reflect quality [59].
Conclusions
This density-equalizing mapping study represents 
the first concise analysis of the global ovarian cancer 
research architecture and illustrates the benefits of sci-
entometrics to assess research output in a standardized 
way. Our study identifies historically interesting aspects 
in the research dynamics and relates these to landmark 
publications in the field. The identification of key manu-
scripts, subject areas as well as journals with high pub-
lication and citation rates guides individual reading and 
the future direction of scientific endeavors. Also, our 
observations highlight the outstanding importance of 
collaborative networks—such as OCAC—that are able to 
produce high quality research and apply for grant fund-
ing successfully in a joint effort. Further, lower-resource 
countries with a high disease burden in their population 
should be included in collaborative networks leading to 
mutual benefits due to the exchange of samples, epide-
miologic data, ideas and gained knowledge.
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